The Six-Month Shield: Lenacapavir Rollout Begins in Zimbabwe Amid Funding Fears
- Southerton Business Times
- 3 hours ago
- 2 min read
Harare, Zimbabwe- Zimbabwe has become one of the first ten African nations to launch the rollout of Lenacapavir, a breakthrough HIV prevention drug developed by Gilead Sciences. Unlike traditional Pre-Exposure Prophylaxis (PrEP), which requires a daily pill, Lenacapavir is administered via an injection every six months, offering what experts call "near-total protection" for high-risk groups.
For sex workers like Constance Mukoloka, the shift from a pill bottle to a biannual injection is not just about convenience, it is about economic survival.
The "Pill Bottle" Stigma: Clients often mistake PrEP for HIV treatment (ART). Seeing a container of pills can lead to fear and lost income.
Adherence: In high-pressure environments where alcohol or unpredictable schedules are factors, a daily pill is easily missed.
Confidentiality: The injection leaves no physical trace in a person's belongings, protecting their privacy and professional standing.
The current phase is a targeted, donor-supported initiative aimed at the most vulnerable demographics:
Target Reach: 46,000 people across 24 sites.
Eligibility: Sex workers, adolescent girls/young women (AGYW), gay men, and pregnant/breastfeeding women.
Funding: Supported by PEPFAR and the Global Fund, as the Zimbabwean government currently lacks the fiscal space for a nationwide mass purchase.
Despite the excitement, Dr. Ernest Chikwati of the Aids Healthcare Foundation urges caution. He notes that while Lenacapavir is a turning point, it is not a "silver bullet."
Cost vs. Access: While the drug is currently free for 46,000 people, scaling to a population of 15 million remains a massive financial hurdle.
Holistic Prevention: Condoms remain the most cost-effective tool against both HIV and STIs, and high-cost injectables must not cannibalize their funding.
Infrastructure Gaps: Maintaining patient engagement at six-month intervals requires a robust tracking system to ensure they return for their second dose.
Cesar Nunez (UNAIDS) warns that the reliance on foreign assistance is a double-edged sword. With aid cuts looming, UNAIDS anticipates that a lack of community-led funding could contribute to 1.4 million new infections annually by 2030 globally.
Lenacapavir HIV prevention Zimbabwe
Comments